Translational Genomics Research Institute: Ashion Analytics Receives Medicare Coverage for GEM ExTra Assay for Patients With Advanced Solid Tumors
July 15, 2020
July 15, 2020
PHOENIX, Arizona, July 15 -- The Translational Genomics Research Institute issued the following news release:
Ashion Analytics LLC announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, GEM ExTra(R), one of the nation's most comprehensive genomic cancer analysis tests.
GEM ExTra, Ashion's flagship clinical assay, detects tumor-specific mutatio . . .
Ashion Analytics LLC announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, GEM ExTra(R), one of the nation's most comprehensive genomic cancer analysis tests.
GEM ExTra, Ashion's flagship clinical assay, detects tumor-specific mutatio . . .